Výsledky vyhledávání

[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]

Autor: G, Mickisch, I, Peters, C, Grüllich, T, Mudra, C, Doehn

Publikováno v: Der Urologe. Ausg. a

Immunotherapies with checkpoint inhibitors have led to a paradigm shift in metastatic renal cell carcinoma (mRCC) as they established a new standard in first-line treatment. In addition to the established monotherapy with tyrosine kinase inhibitors,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6a70896bb7d4799969f79cdfd74e2b28
https://pubmed.ncbi.nlm.nih.gov/33656593

Zobrazit plný text záznamu

Metastasiertes kastrationsresistentes Prostatakarzinom

Autor: P. Albers, S. Zastrow, M-O. Grimm, G. Geiges, G. Mickisch, F. König, Kurt Miller, David G. Pfister, R. Eichenauer, Christian Schwentner, Henrik Suttmann

Publikováno v: Der Urologe. 55:1206-1212

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::92b493e35ed390bb2f899d6667bdbd02
https://doi.org/10.1007/s00120-016-0176-4

Zobrazit plný text záznamu

Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)

Autor: Cezary Szczylik, Alain Ravaud, J-J. Patard, S Kirpekar, Manuela Schmidinger, Bernard Escudier, Timothy Eisen, Joaquim Bellmunt, Martin Gore, G. Mickisch, Patrick Schöffski, S Lewis, Camillo Porta, Cora N. Sternberg

Publikováno v: European Journal of Cancer. 50:3153-3160

The appropriateness of the numerous therapeutic options available for patients with advanced or metastatic renal cell carcinoma (RCC) was evaluated in 2011, using the RAND/University of California, Los Angeles (UCLA) appropriateness methodology to ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44ff464dfb47dd83b97559fc5f4b7433
https://doi.org/10.1016/j.ejca.2014.09.007

Zobrazit plný text záznamu

Metastasiertes kastrationsresistentes Prostatakarzinom

Autor: Christian Schwentner, F. König, S. Zastrow, Kurt Miller, Henrik Suttmann, R. Eichenauer, M-O. Grimm, P. Albers, G. Geiges, David G. Pfister, G. Mickisch

Publikováno v: Der Urologe. 53:710-714

This position paper is intended to help to structure and to standardize therapy monitoring in patients with metastatic castration-resistant prostate cancer (mCRPC). With the treatment options available today, patients with metastatic disease can ofte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7806bd84e038940c52d18d0e9c29a0a0
https://doi.org/10.1007/s00120-014-3491-7

Zobrazit plný text záznamu

[Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring]

Autor: K, Miller, P, Albers, R, Eichenauer, G, Geiges, M-O, Grimm, F, König, G, Mickisch, D, Pfister, C, Schwentner, H, Suttmann, S, Zastrow

Publikováno v: Der Urologe. Ausg. A. 55(9)

Therapies currently available in Germany for metastatic castration-resistant prostate cancer (mCRPC) include docetaxel, cabazitaxel, abiraterone acetate, enzalutamide and radium-223, all of which offer a potential survival benefit that adds up in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::79a41fa78c67439708740581dbccbdc9
https://pubmed.ncbi.nlm.nih.gov/27411995

Zobrazit plný text záznamu

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

Autor: E. De Nigris, Alain Ravaud, Joaquim Bellmunt, S Kirpekar, Bernard Escudier, Martin Gore, G. Mickisch, J-J. Patard, Camillo Porta, Timothy Eisen, C. Wheeler, Manuela Schmidinger, Patrick Schöffski, Cora N. Sternberg, Cezary Szczylik

Publikováno v: European Journal of Cancer. 48:1038-1047

A diverse range of treatment options and interventions are available for the management of renal cell carcinoma (RCC), allowing clinicians to tailor therapy to best meet their patient's needs and situation. However, choosing from the plethora of opti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355870d578c2b0fdc26717855eb4384b
https://doi.org/10.1016/j.ejca.2012.02.058

Zobrazit plný text záznamu

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

Autor: Bernard Escudier, Stefan Walzer, Giuseppe Procopio, G. Mickisch, Martin Gore, Mark Nuijten

Publikováno v: British Journal of Cancer

Background: Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f5a1e0b0e5b500e9ec93c01662f42d
https://doi.org/10.1038/sj.bjc.6605417

Zobrazit plný text záznamu

Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis

Autor: Richard Sylvester, E. David Crawford, H. Van Poppel, G. Mickisch, Robert C. Flanigan, Cathy Tangen

Publikováno v: Journal of Urology. 171:1071-1076

Metastatic renal cancer is associated with a poor prognosis. Recent advances in immunotherapy for this problem have rekindled interest in cytoreductive nephrectomy. We report a combined analysis of 2 prospective randomized trials that used an identic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d214c7aecbf2828bcaa6d002b970e6bb
https://doi.org/10.1097/01.ju.0000110610.61545.ae

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání